Status:
COMPLETED
Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
Brief Summary
This study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in patients with type 2 diabetes during NovoMix® 30 treatment.
Eligibility Criteria
Inclusion
- Any patient with diabetes type 2 diabetes
- Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin
- Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient
Exclusion
- Known or suspected allergy to study product(s) or related products
- Pregnancy, breast-feeding or intention of becoming pregnant within the next 6 months
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
243 Patients enrolled
Trial Details
Trial ID
NCT00729898
Start Date
March 1 2008
End Date
September 1 2010
Last Update
October 31 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Rud, Norway, 1309
2
Novo Nordisk Investigational Site
Farsta, Sweden, 123 47